Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
Metrics to compare | KDST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKDSTPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.2x | −2.0x | −0.6x | |
PEG Ratio | −0.06 | −0.04 | 0.00 | |
Price/Book | −6.2x | 2.0x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.2x | |
Upside (Analyst Target) | - | 414.7% | 46.2% | |
Fair Value Upside | Unlock | 13.5% | 7.0% | Unlock |